PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

Laura Martinez-Verbo; Yoana Veselinova; Pere Llinàs-Arias; Carlos A García-Prieto; Aleix Noguera-Castells; Miguel L Pato; Alberto Bueno-Costa; Ignacio Campillo-Marcos; Lorea Villanueva; Aina Oliver-Caldes; Oriol Cardus; Sergi V Salsench; Almudena García-Ortiz; Antonio Valeri; Elizabeta A Rojas; Naroa Barrena; Norma C Gutiérrez; Felipe Prósper; Xabier Agirre; Carlos Fernández de Larrea; Joaquín Martínez-López; Gerardo Ferrer; Manel Esteller

doi:10.1038/s41375-024-02419-z

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

Leukemia. 2024 Sep 24. doi: 10.1038/s41375-024-02419-z. Online ahead of print.

Authors

Laura Martinez-Verbo¹, Yoana Veselinova¹, Pere Llinàs-Arias¹, Carlos A García-Prieto^{1

2}, Aleix Noguera-Castells¹, Miguel L Pato¹, Alberto Bueno-Costa¹, Ignacio Campillo-Marcos^{1

3}, Lorea Villanueva¹, Aina Oliver-Caldes^{4

5}, Oriol Cardus^{4

5}, Sergi V Salsench^{4

5}, Almudena García-Ortiz^{6

7}, Antonio Valeri^{6

7}, Elizabeta A Rojas⁸, Naroa Barrena⁹, Norma C Gutiérrez^{5

8}, Felipe Prósper^{3

10

11}, Xabier Agirre^{3

10

12}, Carlos Fernández de Larrea^{4

5}, Joaquín Martínez-López^{6

7}, Gerardo Ferrer^{13

14

15}, Manel Esteller^{16

17

18

19}

Affiliations

¹ Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
² Barcelona Supercomputing Center (BSC), Barcelona, Spain.
³ Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.
⁴ Department of Hematology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
⁵ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
⁶ Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
⁷ Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO). Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.
⁸ Department of Hematology, University Hospital of Salamanca, IBSAL, Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.
⁹ Universidad de Navarra, Tecnun Escuela de Ingeniería, San Sebastián, Spain.
¹⁰ Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
¹¹ Servicio de Hematología y Terapia Celular, Clínica Universidad de Navarra (CUN), Pamplona, Spain.
¹² Cancer Centre Clínica Universidad de Navarra (CCUN), Pamplona, Spain.
¹³ Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain. gferrer@carrerasresearch.org.
¹⁴ Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. gferrer@carrerasresearch.org.
¹⁵ Feinstein Institutes for Medical Research, Northwell Health, Manhasset, USA. gferrer@carrerasresearch.org.
¹⁶ Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain. mesteller@carrerasresearch.org.
¹⁷ Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. mesteller@carrerasresearch.org.
¹⁸ Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. mesteller@carrerasresearch.org.
¹⁹ Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain. mesteller@carrerasresearch.org.

PMID: 39322713
DOI: 10.1038/s41375-024-02419-z

No abstract available

Grants and funding

PID2021-125282OB-I00/EC | European Regional Development Fund (Europski Fond za Regionalni Razvoj)